Vivoryon Therapeutics N.V. (0R3M.L)
| Previous close | 0.8300 |
| Open | 0.9000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.9000 - 1.0280 |
| 52-week range | 0.5000 - 19.4000 |
| Volume | |
| Avg. volume | 3,012 |
| Market cap | 134,254 |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease
Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease Additional kidney function analyses strongly support Vivoryon’s shift in strategic focus to inflammatory and fibrotic diseases, and are a further step towards securing Company’s futureVaroglutamstat`s beneficial effect of improving kidney function, as demonstrated by an increase of estimated glomerular filtration rate (eGFR), confirmed by various sensitivity and subgroup analys
- GlobeNewswire
Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 Halle (Saale) / Munich, Germany, May 15, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its first quarter financial results for the period ended March
- GlobeNewswire
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 Halle (Saale) / Munich, Germany, May 08, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that its 2024 Annual General Meeting will be held on Friday, June 21, 2024 at 01:00 p.m. (CEST) at the A
